Letter referencing “Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting in glioma patients receiving adjuvant temozolomide”
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.